All In Biotech

Drug Trial Radar · NCT02760277

An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Last checked: Nov 19, 2026Latest source record: Jul 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

48

Actual

Start

Jul 28, 2016

Primary completion

Apr 26, 2018

Study completion Apr 26, 2018

Sponsor

Lead sponsor
ReveraGen BioPharma, Inc.Industry
Sponsor type
Industry
Collaborators
University of Pittsburgh; National Institute of Neurological Disorders and Stroke (NINDS); Cooperative International Neuromuscular Research Group; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted
May 3, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 4 years, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purposes of this study are to see if it is safe to use a new medication called vamorolone for more than two weeks in children with Duchenne muscular dystrophy (DMD), to see if vamorolone works for the treatment for DMD, and to see how any potential side effects compare to those seen in boys using steroids.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • Vamorolone 0.25 mg/day/dayDrug

    Oral administration of 0.25 mg/kg/day daily for 24 weeks.

  • Vamorolone 0.75 mg/day/dayDrug

    Oral administration of 0.75 mg/kg/day daily for 24 weeks.

  • Vamorolone 2.0 mg/day/dayDrug

    Oral administration of 2.0 mg/kg/day daily for 24 weeks.

  • Vamorolone 6.0 mg/day/dayDrug

    Oral administration of 6.0 mg/kg/day daily for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 weeks
  2. Total Number of Adverse Events as Assessed by CTCAE Version 4.03Time frame: 24 weeks
  3. Muscle Function Measured by Time to Stand Test (TTSTAND)- VelocityTime frame: 002 Baseline, 003 Baseline, 003 Week 12, Week 24 (Note: 002 Baseline is from VBP15-002 4 week study (NCT02760264), previous to VBP15-003)
  4. BMI Z-scoreTime frame: 002 Baseline, 003 Week 12, Week 24

Locations

12 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Davis

    Davis, California

  • University of Florida

    Gainesville, Florida

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital

    Chicago, Illinois

  • Duke University

    Durham, North Carolina

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Royal Children's Hospital

    Melbourne, Australia

  • Sydney Children's Hospital

    Westmead, Australia

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • Schneider Children's Medical Center

    Petah Tikva, Israel

  • Queen Silvia Children's Hospital

    Gothenburg, Sweden

  • Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.